Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR

Watchlist Manager
Arrowhead Pharmaceuticals Inc Logo
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Watchlist
Price: 18.54 USD 1.42% Market Closed
Market Cap: 2.3B USD
Have any thoughts about
Arrowhead Pharmaceuticals Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-3.5
Current
-20.2
Median
4.2
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-3.5
=
Enterprise Value
1.9B USD
/
EBITDA
-529.7m USD
All Countries
Close
EBITDA Growth
US
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Average EV/EBITDA: 17.2
Negative Multiple: -3.5
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-3.3
2-Years Forward
EV/EBITDA
-3.2
3-Years Forward
EV/EBITDA
-3.3

See Also

Discover More